WO2004060887A1 - Verfahren zur herstellung von 5-chlor-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid - Google Patents
Verfahren zur herstellung von 5-chlor-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid Download PDFInfo
- Publication number
- WO2004060887A1 WO2004060887A1 PCT/EP2003/014871 EP0314871W WO2004060887A1 WO 2004060887 A1 WO2004060887 A1 WO 2004060887A1 EP 0314871 W EP0314871 W EP 0314871W WO 2004060887 A1 WO2004060887 A1 WO 2004060887A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carboxylic acid
- amide
- oxo
- propyl
- chlorothiophene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a process for the preparation of 5-chloro-N- ( ⁇ (5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1, 3-oxazolidine-5 -yl ⁇ -methyl) -2- thiophenecarboxamide starting from 5-chlorothiophene-2-carbonylcl ⁇ lorid 5 (2S) -3- aminopropane-l, 2-diol and 4- (4-aminophenyl) -3-morpholinone.
- the compound of formula (I) acts as an inhibitor of the blood coagulation factor Xa and can be used as a means of prophylaxis and / or treatment of thromboembolic disorders, in particular myocardial infarction, angina pectoris (including unstable angina), reocclusions and restenosis after angioplasty or aortic coronary artery bypass, stroke , transient ischemic attacks, peripheral arterial diseases, pulmonary embolism or deep venous thrombosis.
- WO-A 01/47919 also describes a method for preparing the compound of formula (I) starting from 2 - [(2S) -2-oxiranylmethyl] -lH-isoindole-1,3, (2H) -dione (U), 4- (4-aminophenyl) -3-morpholinone (HI) and 5-chlorothiophene-2-carbonyl chloride (IV):
- the epoxyphthalimide (II) is prepared by reacting (2S) -l-chloropropane-2,3-diol (V) with potassium carbonate via the step of (S) -glycidol (VI) and subsequent Mitsunobu reaction with phthalide:
- the glycidol (VT) is particularly sensitive to polymerization in large quantities and therefore not stable in storage, and is also toxic and potentially carcinogenic.
- the Mitsunobu reaction in the preparation of compound (II) is technically complex because, on the one hand, racemization easily occurs in larger batches.
- the atom economy is extremely unsatisfactory because triphenylphosphine oxide and diisopropylazodicarboxylate hydrazide are generated as waste in stoichiometric quantities.
- the nitrogen atom in the oxazolidino ring of the drawing molecule (I) is introduced in a phthalimide-protected manner.
- the phthalic acid residue as a protective group must be removed in the further course of the synthesis, which increases the number of stages and means additional waste.
- the compound of the formula (I) can be obtained in a shortened reaction sequence using storage-stable and less toxic starting materials, starting from 5-chlorothiophene-2-carbonyl chloride (TV), (2S) -3-an ino-propane 1,2-diol hydrochloride (VII) and 4- (4-aminophenyl) -3-morpholinone (HI) can be produced in improved yield.
- TV 5-chlorothiophene-2-carbonyl chloride
- VII (2S) -3-an ino-propane 1,2-diol hydrochloride
- HI 4- (4-aminophenyl) -3-morpholinone
- Nerbinding (IV) can be produced under the usual reaction conditions for the production of carboxylic acid chlorides from the corresponding carboxylic acids.
- the reaction of 5-chlorothiophene-2-carboxylic acid with tbionyl chloride as chlorination reagent in toluene as solvent is preferred.
- the reaction (IV) + (VH) -> (VIII) can take place under the reaction conditions customary for the formation of amide bonds from the corresponding carboxylic acid chlorides and amines.
- a two-phase system consisting of aqueous sodium hydrogen carbonate solution and 2-methyltetrahydroforan as the organic solvent is preferred.
- (2S) -3-Amino-propane-l, 2-diol is used as a free base or as an acid addition salt.
- Preferred is the hydrochloride (VII), which crystallizes better than the free base and is therefore easy to handle.
- To increase the reaction yield either an excess of amine is optionally used or an auxiliary base is added.
- the addition of 1 to 3, preferably 2, equivalents of an auxiliary base such as sodium hydrogen carbonate is preferred.
- the reaction generally takes place in a temperature range from 0 ° C. to 40 ° C., preferably from 5 ° C. to 30 ° C.
- the reaction (VIH) -> (IX) is carried out with 1 to 5, preferably 3 to 5, in particular 4 equivalents of a solution of hydrobromic acid in acetic acid, if appropriate in the presence of acetic anhydride.
- the reaction temperature is between 20 ° C and 80 ° C, preferably between 60 and 65 ° C.
- the amount of methanol added can be varied over a wide range, preferably 40 to 80 moles, in particular 50 to 60 moles, of methanol per mole (VHI) used.
- the solvents are distilled off, preferably in vacuo. The remaining distillation bottoms are optionally neutralized before filtering the product.
- the solvent for the reaction (IX) + (IH) -> (X) can be varied widely, toluene is preferred.
- the reaction temperature is between 80 ° C and 200 ° C, a range between 90 ° C and 110 ° C is preferred.
- the reaction is carried out in the presence of an auxiliary base such as, for example, triemylarnine, diisopropyemylamine or collidine; preference is given to using colhdin.
- the stoichiometry of the reaction and the reaction time can be varied over a wide range, a ratio of compound (IX) to compound (HI) to collidine of 1.2 to 1.0 to 1.0 and a reaction time of 4 to 8, in particular 5 to 6 hours is preferred , - 1 -
- phosgene equivalents are, for example, phosgene substitutes such as di- or triphosgene or carbon monoxide equivalents such as ⁇ , ⁇ -carbonyl-bisimidazole. It is preferred to use 1 to 2 equivalents, in particular 1.1 to 1.3 equivalents, of N.N-carbonylbisknidazole in a solvent mixture of l-methyl-2-pyrrolidone and toluene.
- clarification filtration and / or recrystallization may follow.
- the reaction generally takes place in a temperature range from 20 ° C. to 150 ° C., preferably from 30 ° C. to 110 ° C., in particular from 75 ° C. to 85 ° C.
- the individual stages of the process according to the invention can be carried out at normal, elevated or reduced pressure (for example from 0.5 to 5 bar). Generally one works at normal pressure.
- the solvents are distilled off in vacuo at about 95 mbar.
- the remaining suspension is mixed with 50 ml of 1-butanol and 350 ml of water are added.
- the precipitated product is filtered off, washed with water and dried.
- 25 g of 5-chlorothiophene-2-carboxylic acid- ⁇ (R) -2-hydroxy-3 - [4- (3-oxo-morpholin-4-yl) - phenylamino] propyl ⁇ amide (X) are at 20 to Suspended 25 ° C in 250 ml of toluene and mixed with 37.5 ml of l-methyl-2-pyrrohdone and 11.9 g of N, N-carbonyldii idazole. The reaction mixture is heated to 80 to 83 ° C. for 20 minutes and then to 115 ° C. for one hour. After cooling to 20 ° C filtered off precipitated reaction product, washed twice with 25 ml of water and dried at 60 ° C in a vacuum.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/538,342 US20070149522A1 (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
JP2004564216A JP4667044B2 (ja) | 2003-01-07 | 2003-12-24 | 5−クロロ−n−({(5s)−2−オキソ−3−[4−(3−オキソ−4−モルホリニル)−フェニル]−1,3−オキサゾリジン−5−イル}−メチル)−2−チオフェンカルボキサミドの製造方法 |
DE50313496T DE50313496D1 (de) | 2003-01-07 | 2003-12-24 | VERFAHREN ZUR HERSTELLUNG VON 5-CHLOR- i N /i -({5S)-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&r cub;-METHYL)-2-THIOPHENCARBOXAMID |
AU2003296728A AU2003296728A1 (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({5s)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide |
CA2512504A CA2512504C (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
EP03814467A EP1583761B1 (de) | 2003-01-07 | 2003-12-24 | VERFAHREN ZUR HERSTELLUNG VON 5-CHLOR- i N /i -({5S)-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&r cub;-METHYL)-2-THIOPHENCARBOXAMID |
US12/556,158 US8106192B2 (en) | 2003-01-07 | 2009-09-09 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10300111.5 | 2003-01-07 | ||
DE10300111A DE10300111A1 (de) | 2003-01-07 | 2003-01-07 | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/538,342 A-371-Of-International US20070149522A1 (en) | 2003-01-07 | 2003-12-24 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
US12/556,158 Division US8106192B2 (en) | 2003-01-07 | 2009-09-09 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004060887A1 true WO2004060887A1 (de) | 2004-07-22 |
Family
ID=32519617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/014871 WO2004060887A1 (de) | 2003-01-07 | 2003-12-24 | Verfahren zur herstellung von 5-chlor-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
Country Status (8)
Country | Link |
---|---|
US (2) | US20070149522A1 (de) |
EP (1) | EP1583761B1 (de) |
JP (1) | JP4667044B2 (de) |
AU (1) | AU2003296728A1 (de) |
CA (1) | CA2512504C (de) |
DE (2) | DE10300111A1 (de) |
ES (1) | ES2360097T3 (de) |
WO (1) | WO2004060887A1 (de) |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005068456A1 (de) * | 2004-01-15 | 2005-07-28 | Bayer Healthcare Ag | Herstellverfahren |
EP1723164A1 (de) * | 2004-03-03 | 2006-11-22 | Sanofi-Aventis Deutschland GmbH | BETA-AMINOSÄUREDERIVATE ALS FAKTOR Xa-INHIBITOREN |
WO2007039132A1 (de) * | 2005-10-04 | 2007-04-12 | Bayer Healthcare Ag | Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid |
WO2009018807A1 (de) * | 2007-08-06 | 2009-02-12 | Schebo Biotech Ag | Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie |
US7767702B2 (en) | 2001-06-20 | 2010-08-03 | Bayer Schering Pharma Aktiengesellschaft | Substituted oxazolidinones for combinational therapy |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
WO2011012321A1 (en) | 2009-07-31 | 2011-02-03 | Krka, D.D., Novo Mesto | Processes for crystallization of rivaroxaban |
EP2292616A1 (de) | 2005-10-04 | 2011-03-09 | Bayer Schering Pharma Aktiengesellschaft | Neue polymorphe Form und die amorphe Form von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
US7932278B2 (en) | 2005-09-23 | 2011-04-26 | Bayer Schering Pharma Aktiengesellschaft | 2-aminoethoxyacetic acid derivatives and their use |
WO2011080341A1 (en) * | 2010-01-04 | 2011-07-07 | Enantia, S.L. | Process for the preparation of rivaroxaban and intermediates thereof |
EP2354128A1 (de) | 2010-02-10 | 2011-08-10 | Sandoz Ag | Verfahren zur Herstellung von Rivaroxaban |
EP2404920A1 (de) | 2010-07-06 | 2012-01-11 | Sandoz AG | Kristalline Form von Rivaroxaban-Dihydrat |
US8106192B2 (en) | 2003-01-07 | 2012-01-31 | Bayer Pharma Aktiengesellschaft | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
US8129378B2 (en) | 1999-12-24 | 2012-03-06 | Bayer Pharma Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
WO2012140061A1 (en) | 2011-04-11 | 2012-10-18 | Sandoz Ag | Method for the preparation of substituted oxazolidinones |
WO2012153155A1 (en) * | 2011-05-06 | 2012-11-15 | Egis Gyógyszergyár Nyilvãnosan Müködö Részvény-Társaság | Process for the preparation of a rivaroxaban and intermediates formed in said process |
WO2012159992A1 (en) | 2011-05-20 | 2012-11-29 | Interquim, S.A. | Process for obtaining rivaroxaban and intermediate thereof |
WO2013098833A2 (en) | 2011-09-08 | 2013-07-04 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
WO2013120464A1 (en) | 2012-02-17 | 2013-08-22 | Zentiva, K.S. | A process for the preparation of rivaroxaban based on saving of 1,1'-carbonyl diimidazole. |
WO2013120465A1 (en) | 2012-02-16 | 2013-08-22 | Zentiva, K.S. | A process for the preparation of rivaroxaban based on the use of (s)-epichlorohydrin |
EP2630143A1 (de) * | 2010-10-18 | 2013-08-28 | Apotex Pharmachem Inc. | Verfahren zur herstellung von rivaroxaban und zwischenprodukten davon |
WO2013156936A1 (en) * | 2012-04-16 | 2013-10-24 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban and intermediates thereof |
WO2013175431A1 (en) * | 2012-05-24 | 2013-11-28 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
CN104098558A (zh) * | 2014-07-22 | 2014-10-15 | 常州市第四制药厂有限公司 | 酰胺类化合物及其制备方法 |
CN104693139A (zh) * | 2011-01-07 | 2015-06-10 | 浙江九洲药业股份有限公司 | 一种合成利伐沙班中间体的新工艺 |
WO2016062828A1 (en) | 2014-10-22 | 2016-04-28 | Zaklady Farmaceutyczne Polpharma S.A | Process for preparing a polymorph of rivaroxaban |
US9359341B2 (en) | 2012-12-26 | 2016-06-07 | Wanbury Ltd. | Aldehyde derivative of substitute oxazolidinones |
US9394292B2 (en) | 2012-12-26 | 2016-07-19 | Wanbury Ltd. | Rivaroxaban intermediate and preparation thereof |
US9402851B2 (en) | 2003-11-27 | 2016-08-02 | Bayer Intellectual Property Gmbh | Process for the preparation of a solid, orally administrable pharmaceutical composition |
US9539218B2 (en) | 2005-01-31 | 2017-01-10 | Bayer Intellectual Property Gmbh | Prevention and treatment of thromboembolic disorders |
KR101811123B1 (ko) | 2016-02-19 | 2017-12-20 | 일동제약(주) | 신규의 모르폴린 이인산염 및 이를 이용한 고순도 리바록사반의 제조방법 |
EP3309158A1 (de) | 2012-12-21 | 2018-04-18 | Farma GRS, d.o.o. | Cristalline form k von rivaroxaban and verfahren zur herstellung |
CN109481445A (zh) * | 2018-12-19 | 2019-03-19 | 黄泳华 | 含有吗啉酮类化合物的组合物 |
WO2022180531A1 (en) | 2021-02-23 | 2022-09-01 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
EP4201933A1 (de) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Kristallisationsverfahren für rivaroxaban |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537184A (ja) * | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血小板剤に対する耐性を治療するためのジピリダモールの使用 |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
DE102007028320A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007032345A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
DE102007032347A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
DE102007037373A1 (de) | 2007-08-06 | 2009-02-19 | Schebo Biotech Ag | Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie |
US20100168111A1 (en) * | 2008-12-31 | 2010-07-01 | Apotex Pharmachem Inc. | Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide |
HU230734B1 (hu) | 2011-10-10 | 2017-12-28 | EGIS Gyógyszergyár Nyrt | Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok |
CN103288814B (zh) | 2012-02-24 | 2016-07-06 | 国药集团国瑞药业有限公司 | 一种利伐沙班中间体的制备方法 |
WO2013152168A1 (en) | 2012-04-06 | 2013-10-10 | Indiana University Research And Technology Corporation | Processes for preparing rivaroxaban |
EP2844654B1 (de) | 2012-05-02 | 2021-03-10 | Symed Labs Limited | Verbessertes verfahren zur herstellung von rivaroxaban unter verwendung neuartiger zwischenprodukte |
EP2900663A2 (de) | 2012-09-26 | 2015-08-05 | Ranbaxy Laboratories Limited | Verfahren zur herstellung von rivaroxaban |
CN103864771A (zh) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | 一种利伐沙班的制备方法 |
US9663505B2 (en) | 2013-03-25 | 2017-05-30 | Glenmark Pharmaceuticals Limited | Process for the preparation of rivaroxaban |
CN103351385A (zh) * | 2013-06-28 | 2013-10-16 | 浙江燎原药业有限公司 | 一种利伐沙班中间体的制备方法 |
WO2015011617A1 (en) | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
IN2013MU02699A (de) | 2013-08-19 | 2015-06-19 | Amneal Pharmaceuticals Llc | |
CN103524447B (zh) * | 2013-10-24 | 2015-04-22 | 山东铂源药业有限公司 | 一种利伐沙班中间体4-(4-氨基苯基)-3-吗啉酮的合成方法 |
CN103724336B (zh) * | 2013-12-24 | 2015-10-21 | 悦康药业集团有限公司 | 一种新型抗凝血药物的合成方法 |
WO2016030669A1 (en) | 2014-08-25 | 2016-03-03 | Cipla Limited | Process for the preparation of rivaroxaban |
CN105503903B (zh) * | 2014-09-26 | 2019-04-26 | 华北制药集团新药研究开发有限责任公司 | 苯并恶唑并恶嗪酮类化合物的制备方法及其中间体和晶型 |
CN109280053A (zh) * | 2018-10-11 | 2019-01-29 | 东南大学 | 利伐沙班噁唑烷杂质对照品及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047919A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung |
WO2003000256A1 (de) * | 2001-06-20 | 2003-01-03 | Bayer Healthcare Ag | Kombinationstherapie substituierter oxazolidinone |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811555A (en) * | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) * | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
LU80081A1 (fr) * | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) * | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) * | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4259201A (en) * | 1979-11-09 | 1981-03-31 | The Procter & Gamble Company | Detergent composition containing organic peracids buffered for optimum performance |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
HU190072B (en) * | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
ES533097A0 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
EP0316594B1 (de) | 1987-10-21 | 1993-09-29 | The Du Pont Merck Pharmaceutical Company | Aminomethyl-oxo-oxazolidinyl-ethenylbenzen-Derivate, nützlich als antibakterielles Mittel |
US4977173A (en) * | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5254577A (en) * | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US4948801A (en) * | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US5139788A (en) * | 1989-10-17 | 1992-08-18 | Ecolab Inc. | Noncontaminating antimicrobial composition |
AU667198B2 (en) | 1991-11-01 | 1996-03-14 | Pharmacia & Upjohn Company | Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents |
US5264229A (en) * | 1992-04-20 | 1993-11-23 | Degussa Corporation | Shelf life extension for commercially processed poultry/fowl and seafood products using a specialized hydrogen peroxide |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
US5349045A (en) * | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
ATE181735T1 (de) * | 1993-05-01 | 1999-07-15 | Merck Patent Gmbh | Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten |
JP3255499B2 (ja) * | 1993-06-16 | 2002-02-12 | 花王株式会社 | 新規スルホナート、その製造法及びこれを含有する漂白剤組成物 |
US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
US5362899A (en) * | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
DE4332384A1 (de) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
US5374369A (en) * | 1993-10-14 | 1994-12-20 | Lever Brothers Company, Division Of Conopco, Inc. | Silver anti-tarnishing detergent composition |
US5910504A (en) * | 1995-02-03 | 1999-06-08 | Pharmacia & Upjohn | Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials |
US5683977A (en) * | 1995-03-06 | 1997-11-04 | Lever Brothers Company, Division Of Conopco, Inc. | Dry cleaning system using densified carbon dioxide and a surfactant adjunct |
US5656571A (en) * | 1995-04-05 | 1997-08-12 | Deerpoint Industries, Inc. | Polyolefinic adjuvants |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
US5698506A (en) * | 1995-05-19 | 1997-12-16 | Lever Brothers Company, Division Of Conopco, Inc. | Automatic dishwashing compositions containing aluminum salts |
DE19524765A1 (de) * | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
AU716493B2 (en) | 1995-09-01 | 2000-02-24 | Pharmacia & Upjohn Company | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings |
EP1019385B1 (de) | 1995-09-15 | 2004-01-14 | PHARMACIA & UPJOHN COMPANY | Aminoaryl oxazolidinone n-oxide |
DE19601264A1 (de) * | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
HRP970049A2 (en) * | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
US6310025B1 (en) * | 1996-03-04 | 2001-10-30 | The Procter & Gamble Company | Laundry pretreatment process and bleaching compositions |
US5968885A (en) * | 1996-04-22 | 1999-10-19 | Procter & Gamble Co. | Bleaching compositions |
MA25183A1 (fr) * | 1996-05-17 | 2001-07-02 | Arthur Jacques Kami Christiaan | Compositions detergentes |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
DK1175902T3 (da) | 1996-07-15 | 2005-12-19 | Sankyo Co | Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose |
US5935724A (en) * | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
JP2002501530A (ja) | 1997-05-30 | 2002-01-15 | ファルマシア・アンド・アップジョン・カンパニー | チオカルボニル官能基を有するオキサゾリジノン抗菌剤 |
NZ502253A (en) * | 1997-07-11 | 2001-06-29 | Upjohn Co | Thiadiazolyl and oxadiazolyl phenyl oxazolidinone derivatives which are antibacterial agents |
DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
US6444634B1 (en) * | 1997-09-11 | 2002-09-03 | The Procter & Gamble Company | Bleaching compositions |
DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
US5998406A (en) | 1997-11-12 | 1999-12-07 | Pharmacia & Upjohn Company | Oxazolidinone derivatives and pharmaceutical compositions |
US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
DE19802239A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Neue mit Bicyclen substituierte Oxazolidinone |
BR9907183A (pt) | 1998-01-23 | 2003-06-10 | Versicor Inc | Colet neas combinatórias de oxazolidinona, composições e processos de preparação |
DE69934093T2 (de) | 1998-01-27 | 2007-06-21 | Aventis Pharmaceuticals Inc. | SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER |
DE19805117A1 (de) | 1998-02-09 | 1999-08-12 | Bayer Ag | Neue Oxazolidinone mit azolhaltigen Tricyclen |
US20010029351A1 (en) * | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
ATE222115T1 (de) * | 1998-05-18 | 2002-08-15 | Upjohn Co | Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate |
DE19842753A1 (de) * | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
US6346279B1 (en) * | 1998-12-14 | 2002-02-12 | Virox Technologies, Inc. | Hydrogen peroxide disinfectant with increased activity |
PE20010851A1 (es) * | 1999-12-14 | 2001-08-17 | Upjohn Co | Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina |
SK7572002A3 (en) * | 1999-12-21 | 2002-12-03 | Upjohn Co | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
KR20020063609A (ko) * | 1999-12-28 | 2002-08-03 | 아지노모토 가부시키가이샤 | 아스파탐 유도체 결정 |
JP4562341B2 (ja) * | 2000-02-15 | 2010-10-13 | ストライク、インベストメンツ、リミテッド、ライアビリティ、カンパニー | 疎水性漂白剤の使用による織物へのパーマネントプレス加工適用方法 |
US6830591B1 (en) * | 2000-02-15 | 2004-12-14 | The Procter & Gamble Company | Method for the use of hydrophobic bleaching systems in textile preparation |
ATE368764T1 (de) * | 2000-02-15 | 2007-08-15 | Procter & Gamble | Einstufiges verfahren zur herstellung von textilien |
DE10105989A1 (de) * | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10110438A1 (de) * | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) * | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) * | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10152460A1 (de) * | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
US20030161882A1 (en) * | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) * | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004002044A1 (de) * | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (de) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prophylaxe und Behandlung von thrombolischen Erkrankungen |
US7754670B2 (en) * | 2005-07-06 | 2010-07-13 | Ecolab Inc. | Surfactant peroxycarboxylic acid compositions |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
US8188270B2 (en) | 2005-10-04 | 2012-05-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102005047558A1 (de) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005048824A1 (de) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
-
2003
- 2003-01-07 DE DE10300111A patent/DE10300111A1/de not_active Withdrawn
- 2003-12-24 ES ES03814467T patent/ES2360097T3/es not_active Expired - Lifetime
- 2003-12-24 DE DE50313496T patent/DE50313496D1/de not_active Expired - Lifetime
- 2003-12-24 JP JP2004564216A patent/JP4667044B2/ja not_active Expired - Fee Related
- 2003-12-24 CA CA2512504A patent/CA2512504C/en not_active Expired - Fee Related
- 2003-12-24 AU AU2003296728A patent/AU2003296728A1/en not_active Abandoned
- 2003-12-24 EP EP03814467A patent/EP1583761B1/de not_active Expired - Fee Related
- 2003-12-24 US US10/538,342 patent/US20070149522A1/en not_active Abandoned
- 2003-12-24 WO PCT/EP2003/014871 patent/WO2004060887A1/de active Application Filing
-
2009
- 2009-09-09 US US12/556,158 patent/US8106192B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001047919A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung |
WO2003000256A1 (de) * | 2001-06-20 | 2003-01-03 | Bayer Healthcare Ag | Kombinationstherapie substituierter oxazolidinone |
Non-Patent Citations (2)
Title |
---|
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002278203, Database accession no. 8822985 * |
J.ORG.CHEM, vol. 67, no. 11, 2002, pages 3933 - 3936 * |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129378B2 (en) | 1999-12-24 | 2012-03-06 | Bayer Pharma Aktiengesellschaft | Substituted oxazolidinones and their use in the field of blood coagulation |
US8530505B2 (en) | 1999-12-24 | 2013-09-10 | Bayer Intellectual Property Gmbh | Substituted oxazolidinones and their use in the field of blood coagulation |
US8822458B2 (en) | 1999-12-24 | 2014-09-02 | Bayer Intellectual Property Gmbh | Substituted oxazolidinones and their use in the field of blood coagulation |
US7767702B2 (en) | 2001-06-20 | 2010-08-03 | Bayer Schering Pharma Aktiengesellschaft | Substituted oxazolidinones for combinational therapy |
US8106192B2 (en) | 2003-01-07 | 2012-01-31 | Bayer Pharma Aktiengesellschaft | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide |
US9402851B2 (en) | 2003-11-27 | 2016-08-02 | Bayer Intellectual Property Gmbh | Process for the preparation of a solid, orally administrable pharmaceutical composition |
US9415053B2 (en) | 2003-11-27 | 2016-08-16 | Bayer Intellectual Property Gmbh | Solid, orally administrable pharmaceutical composition |
US7351823B2 (en) | 2004-01-15 | 2008-04-01 | Bayer Healthcare Ag | Preparation process |
WO2005068456A1 (de) * | 2004-01-15 | 2005-07-28 | Bayer Healthcare Ag | Herstellverfahren |
EP1723164A1 (de) * | 2004-03-03 | 2006-11-22 | Sanofi-Aventis Deutschland GmbH | BETA-AMINOSÄUREDERIVATE ALS FAKTOR Xa-INHIBITOREN |
US9539218B2 (en) | 2005-01-31 | 2017-01-10 | Bayer Intellectual Property Gmbh | Prevention and treatment of thromboembolic disorders |
US7932278B2 (en) | 2005-09-23 | 2011-04-26 | Bayer Schering Pharma Aktiengesellschaft | 2-aminoethoxyacetic acid derivatives and their use |
AU2006299126B2 (en) * | 2005-10-04 | 2012-06-28 | Bayer Intellectual Property Gmbh | Novel polymorphous form and the amorphous form of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
CN101282968B (zh) * | 2005-10-04 | 2013-04-24 | 拜耳知识产权有限责任公司 | 多晶态形式和非晶态形式的5-氯-n-({(5s)-2-氧-3-[4-(3-氧-4-吗啉基)-苯基]-1,3-*唑烷-5-基}-甲基)-2-噻吩羧酰胺 |
EP2292616A1 (de) | 2005-10-04 | 2011-03-09 | Bayer Schering Pharma Aktiengesellschaft | Neue polymorphe Form und die amorphe Form von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
JP2009510140A (ja) * | 2005-10-04 | 2009-03-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 5−クロロ−n−({(5s)−2−オキソ−3−[4−(3−オキソ−4−モルホリニル)−フェニル]−1,3−オキサゾリジン−5−イル}−メチル)−2−チオフェンカルボキサミドの新規多形および無定形 |
NO341632B1 (no) * | 2005-10-04 | 2017-12-11 | Bayer Ip Gmbh | Ny polymorf form av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid |
WO2007039132A1 (de) * | 2005-10-04 | 2007-04-12 | Bayer Healthcare Ag | Neue polymorphe form und die amorphe form von 5-chlor-n- ( { ( 5s ) -2-0x0-3-[4-( 3-oxo-4-morpholinyl) - phenyl] -1,3-oxazolidin-5-yl} -methyl) -2- thiophencarboxamid |
US8188270B2 (en) | 2005-10-04 | 2012-05-29 | Bayer Schering Pharma Aktiengesellschaft | Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide |
WO2009018807A1 (de) * | 2007-08-06 | 2009-02-12 | Schebo Biotech Ag | Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
US8101609B2 (en) | 2009-04-28 | 2012-01-24 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
EA031064B1 (ru) * | 2009-07-31 | 2018-11-30 | КРКА, д.д., НОВО МЕСТО | Способы кристаллизации ривароксабана |
EA031064B2 (ru) * | 2009-07-31 | 2020-07-01 | КРКА, д.д., НОВО МЕСТО | Способы кристаллизации ривароксабана |
WO2011012321A1 (en) | 2009-07-31 | 2011-02-03 | Krka, D.D., Novo Mesto | Processes for crystallization of rivaroxaban |
WO2011080341A1 (en) * | 2010-01-04 | 2011-07-07 | Enantia, S.L. | Process for the preparation of rivaroxaban and intermediates thereof |
WO2011098501A1 (en) | 2010-02-10 | 2011-08-18 | Sandoz Ag | Method for the preparation of rivaroxaban |
EP2354128A1 (de) | 2010-02-10 | 2011-08-10 | Sandoz Ag | Verfahren zur Herstellung von Rivaroxaban |
US8648189B2 (en) | 2010-02-10 | 2014-02-11 | Sandoz Ag | Method for the preparation of rivoraxaban |
EP2404920A1 (de) | 2010-07-06 | 2012-01-11 | Sandoz AG | Kristalline Form von Rivaroxaban-Dihydrat |
US9266868B2 (en) | 2010-07-06 | 2016-02-23 | Sandoz Ag | Crystalline form of rivaroxaban dihydrate |
WO2012004245A1 (en) | 2010-07-06 | 2012-01-12 | Sandoz Ag | Crystalline form of rivaroxaban dihydrate |
EP2630143A1 (de) * | 2010-10-18 | 2013-08-28 | Apotex Pharmachem Inc. | Verfahren zur herstellung von rivaroxaban und zwischenprodukten davon |
EP2630143A4 (de) * | 2010-10-18 | 2014-04-02 | Apotex Pharmachem Inc | Verfahren zur herstellung von rivaroxaban und zwischenprodukten davon |
CN104693139B (zh) * | 2011-01-07 | 2017-04-19 | 浙江九洲药业股份有限公司 | 一种合成利伐沙班中间体的新工艺 |
CN104693139A (zh) * | 2011-01-07 | 2015-06-10 | 浙江九洲药业股份有限公司 | 一种合成利伐沙班中间体的新工艺 |
WO2012140061A1 (en) | 2011-04-11 | 2012-10-18 | Sandoz Ag | Method for the preparation of substituted oxazolidinones |
EA024685B1 (ru) * | 2011-05-06 | 2016-10-31 | Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг | Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе |
MD4557B1 (ro) * | 2011-05-06 | 2018-03-31 | Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu |
WO2012153155A1 (en) * | 2011-05-06 | 2012-11-15 | Egis Gyógyszergyár Nyilvãnosan Müködö Részvény-Társaság | Process for the preparation of a rivaroxaban and intermediates formed in said process |
US9556163B2 (en) | 2011-05-06 | 2017-01-31 | Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag | Process for the preparation of a rivaroxaban and intermediates formed in said process |
WO2012159992A1 (en) | 2011-05-20 | 2012-11-29 | Interquim, S.A. | Process for obtaining rivaroxaban and intermediate thereof |
WO2013098833A2 (en) | 2011-09-08 | 2013-07-04 | Cadila Healthcare Limited | Processes and intermediates for preparing rivaroxaban |
WO2013120465A1 (en) | 2012-02-16 | 2013-08-22 | Zentiva, K.S. | A process for the preparation of rivaroxaban based on the use of (s)-epichlorohydrin |
WO2013120464A1 (en) | 2012-02-17 | 2013-08-22 | Zentiva, K.S. | A process for the preparation of rivaroxaban based on saving of 1,1'-carbonyl diimidazole. |
WO2013156936A1 (en) * | 2012-04-16 | 2013-10-24 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban and intermediates thereof |
WO2013175431A1 (en) * | 2012-05-24 | 2013-11-28 | Ranbaxy Laboratories Limited | Process for the preparation of rivaroxaban |
EP3309158B1 (de) | 2012-12-21 | 2022-03-16 | Krka, tovarna zdravil, d.d. | Kristalline form k von rivaroxaban and verfahren zur herstellung |
EP3309158A1 (de) | 2012-12-21 | 2018-04-18 | Farma GRS, d.o.o. | Cristalline form k von rivaroxaban and verfahren zur herstellung |
US9359341B2 (en) | 2012-12-26 | 2016-06-07 | Wanbury Ltd. | Aldehyde derivative of substitute oxazolidinones |
US9394292B2 (en) | 2012-12-26 | 2016-07-19 | Wanbury Ltd. | Rivaroxaban intermediate and preparation thereof |
CN104098558B (zh) * | 2014-07-22 | 2016-07-06 | 常州市第四制药厂有限公司 | 酰胺类化合物及其制备方法 |
CN104098558A (zh) * | 2014-07-22 | 2014-10-15 | 常州市第四制药厂有限公司 | 酰胺类化合物及其制备方法 |
WO2016062828A1 (en) | 2014-10-22 | 2016-04-28 | Zaklady Farmaceutyczne Polpharma S.A | Process for preparing a polymorph of rivaroxaban |
KR101811123B1 (ko) | 2016-02-19 | 2017-12-20 | 일동제약(주) | 신규의 모르폴린 이인산염 및 이를 이용한 고순도 리바록사반의 제조방법 |
CN109481445A (zh) * | 2018-12-19 | 2019-03-19 | 黄泳华 | 含有吗啉酮类化合物的组合物 |
WO2022180531A1 (en) | 2021-02-23 | 2022-09-01 | Teva Pharmaceutical Industries Ltd | Fixed-dose pharmaceutical compositions |
EP4201933A1 (de) | 2021-12-23 | 2023-06-28 | Zaklady Farmaceutyczne Polpharma S.A. | Kristallisationsverfahren für rivaroxaban |
WO2023118560A1 (en) | 2021-12-23 | 2023-06-29 | Zaklady Farmaceutyczne Polpharma S.A | Crystallisation process for rivaroxaban |
Also Published As
Publication number | Publication date |
---|---|
US20100081807A1 (en) | 2010-04-01 |
DE10300111A1 (de) | 2004-07-15 |
US8106192B2 (en) | 2012-01-31 |
EP1583761A1 (de) | 2005-10-12 |
DE50313496D1 (de) | 2011-04-07 |
JP2006513227A (ja) | 2006-04-20 |
US20070149522A1 (en) | 2007-06-28 |
CA2512504C (en) | 2012-08-21 |
EP1583761B1 (de) | 2011-02-23 |
JP4667044B2 (ja) | 2011-04-06 |
AU2003296728A1 (en) | 2004-07-29 |
CA2512504A1 (en) | 2004-07-22 |
ES2360097T3 (es) | 2011-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1583761B1 (de) | VERFAHREN ZUR HERSTELLUNG VON 5-CHLOR- i N /i -({5S)-2-OXO-3- 4-(3-OXO-4-MORPHOLINYL)-PHENYL -1,3-OXAZOLIDIN-5-YL&r cub;-METHYL)-2-THIOPHENCARBOXAMID | |
EP1720866B1 (de) | Herstellverfahren | |
CH624395A5 (de) | ||
JPS62255495A (ja) | フロ〔3,4−d〕ピリミジン−2,4−ジオン誘導体類およびそれらの中間生成物類 | |
PL190622B1 (pl) | Nowe związki typu piperazyny, kompozycja farmaceutyczna zawierająca te związki oraz sposób wytwarzania tych związków | |
US3120540A (en) | Bis (polymethyl)-4-piperidinol alkanoates | |
DE3522579A1 (de) | Neue 1,4-dihydropyridin-derivate und salze derselben, verfahren zur herstellung derselben und pharmazeutische mittel mit einem gehalt derselben | |
DE3150334A1 (de) | "bis-(carboxamid)-derivate" | |
CN101481323B (zh) | 苯并环庚烯类衍生物、其制备方法及医药用途 | |
CH633542A5 (de) | Verfahren zur herstellung von harnstoffderivaten. | |
JPS61167673A (ja) | (イソキサゾール‐3‐イル)アリールメタノンおよびその製造方法 | |
EP0317845A2 (de) | Substituierte Hydroxylamine | |
JPH023633A (ja) | 新規トリ置換アミン、その製造方法および該アミンを含有する、心臓および循環器疾病の治療薬 | |
HU208970B (en) | Process for producing new thienloxyalkyl derivatives and pharmaceutical compositions comprising same | |
KR880001715B1 (ko) | 1-푸릴-3,4-디하이드로이소퀴놀린의 제조방법 | |
CH627740A5 (de) | Verfahren zur herstellung von substituierten sulfoximidsalzen. | |
CZ239496A3 (en) | Substituted 4h-pyrans, process of their preparation, their use and pharmaceutical composition containing thereof | |
DE3600332C2 (de) | Verfahren zur Herstellung von Pyron-3-carboxamidverbindungen | |
JPS62103069A (ja) | 新規ベンズアミド、その製造方法およびこれを含む薬剤 | |
EP1802311B1 (de) | 4-aminophenyl-morpholinon-derivate zur behandlung von hepatitis c | |
EP0533014A1 (de) | Indolsulfonamid substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
EP0363869B1 (de) | Substituierte thienylethylamine und Verfahren zu deren Herstellung | |
EP2563762B1 (de) | Verfahren zur herstellung substituierter pyridin- 2 - one | |
AT276372B (de) | Verfahren zur Herstellung von neuen N-(tert.-Aminoalkyl)-amidderivaten und deren Säureadditionssalzen | |
DE1670011C3 (de) | Am Kohlenstoff des Heterocyclus alkylierte NJV'-disubstituierte Diazacycloalkane und diese enthaltende Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003814467 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004564216 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2512504 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003814467 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007149522 Country of ref document: US Ref document number: 10538342 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10538342 Country of ref document: US |